We aim to improve the accuracy and efficiency of anatomic pathology by transforming a manual, analog, and qualitative field into an automated, digitized and quantitative medical science. Our technology will serve medical research and biotechnology industry customers who are creating new diagnostics and therapeutic solutions to improve clinical outcomes and save lives.

3T Biosciences is solving a major bottleneck in the field of immunotherapy – identifying novel targets that can be used to generate therapies to treat cancer in broad patient populations. We are developing transformative T cell receptor therapies for cancer and other immune-related diseases. Our proprietary experimental and computational technology allows us to identify novel T cell receptor targets as well as clinical toxicities to bring safe and effective therapies.

Pharmaceutical companies are pursuing increasingly challenging targets, which often require binding to multiple proteins or specificity between closely related proteins. Drug development currently requires iterative screening against one target at a time. This approach is slow, costly, and often ineffective at producing successful therapeutics. A-Alpha Bio has developed a proprietary synthetic biology platform, called AlphaSeq, that enables screening against thousands of targets in a single experimental step. An all-at-once approach saves time, reduces cost, and improves success rates.

Arzeda Corporation is inspired by the efficiency, elegance and simplicity of Nature’s synthetic biological processes. Through our foundation in experimental biology, biochemistry and computational design algorithms, we want to expand the horizons of Nature’s chemical and enzyme-engineering capabilities to provide clever solutions for today’s most pressing global needs. By combining the basic biological tools provided by Nature with our advanced understanding of computational design, Arzeda creates innovative cell factories that can transform or supplement current chemical production methods. Our technology enables us to constantly push the boundaries of our understanding and utilization of biological systems to better meet the needs of our industrial customers and partners. Arzeda believes that our ambitious aims are best achieved in a vibrant discovery environment that fosters creativity, integrity and a dedication to scientific rigor and perseverance.

Atomwise is the creator of AtomNet, the first Deep Learning technology for novel small molecule discovery, characterized by its unprecedented speed, accuracy, and diversity.

Research groups that partner with Atomwise gain powerful advantages in the scope, scale, and success rates of their drug discovery programs.

Offering unprecedented views of the immune system for drug discovery

We are developing next generation technology to store digital information in DNA molecules. Our vision is to fit the information content of entire data centers into the palm of your hand.

We have proven our approach to encoding data in DNA and are in the process of scaling up our platform. The CATALOG technology will make it economically attractive to use DNA as the major medium for long-term archival of data.

Investment Exited - Exit News

Cleversafe sells an object storage system, which it calls the Dispersed Storage Network or dsNet. Cleversafe was founded in Chicago, Illinois in 2004 by S. Christopher Gladwin and was originally based in IIT's technology incubator.

Elysium’s mission is to solve the biggest challenges in health with science, to help people live healthier, longer. Working directly with the world’s leading scientists and clinicians, Elysium translates advances in science and technology into effective, scientifically sound health products that work.

Emerald Cloud Lab (ECL) builds and operates remote-control life sciences laboratories. Scientists anywhere in the world can use ECL software to design experiments as if they’re standing in front of the instruments themselves. Those experiments then run in an ECL automated laboratory facility, with all scientifically relevant variables captured, stored, and made accessible to the user in the company’s knowledge graph database.

Emerald Therapeutics is engineering a novel technology platform for curing persistent viral infections. Founded in 2010 by two scientists and life-long friends from Philadelphia, Emerald is striving to develop a systematic and scalable way to create these new pharmaceuticals.

Emulate Inc.’s Organs-on-Chips technology places living human cells in micro-engineered environments – to recreate human biology. Emulate's integrated system provides a window into the inner-workings of the human body, and is designed to predict human response with greater precision and detail than today’s cell culture or animal-based testing experimental methods.

We are developing innovative tools for allergists to improve patient outcomes

Ginkgo Bioworks is engineering from nature. Its founders, who hail from MIT and include renowned computer scientist Tom Knight, are redesigning industrial engineering for a new generation, creating a revolution powered by biology.

GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.

HelixNano leverages synthetic biology and AI to develop novel therapeutic modalities for the world’s most lethal cancers.

Welcome to the era of health intelligence. Human Longevity, Inc. (HLI) is revolutionizing human health by generating more data and deeper understanding into what can keep you living healthier longer. HLI’s scientists have created the world’s largest database of sequenced genomes and phenotypic (physical traits) data, to uncover unprecedented insights capable of transforming healthcare from reactive to proactive.

We started with this idea that we would build a food system that makes it really easy for people to eat well. How do you create a system like that? And could we get it done in our lifetime? How would that change things? And what would we need to do, day-to-day, as a company, to make that happen? It starts with the tools. There happen to be over 300,000 of them. 300,000+ species of plants all around the world that have never been explored for how they can make our cookies or pasta or ice cream or butter or scrambled eggs better. So, we literally started to explore them by hand. The interest was finding plants that, because of their health, sustainability impact and potential to make delicious food, will help us achieve our mission.

All disease pathogens have a unique genome. Our product detects this genetic information using nucleic acid amplification, the same technique used in laboratory tests. This provides a highly accurate diagnosis of your disease so you know exactly what's wrong and how to fix it.

Founded in 2010, Lygos is providing biotechnology solutions for today’s renewable chemical challenges. We engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production

There are places in the world, including the majority of Africa and Asia, which completely lack usable roads. A billion people in the world have no access to all-season roads. Alright, so let’s build more roads, right? The solution is not that simple. In order to build African road infrastructure equivalent to America’s, it would take 23 years and cost $4 trillion. In the meantime, millions of people would continue to die each year because they lack access to basic resources such as food and medicine.

A simple blood test to detect disease at the molecular level. We believe everyone should have access to accurate, affordable and minimally invasive diagnostic tools.

Our mission is to enable temperature-sensitive vaccines and therapeutics to be stable without refrigeration so they can be easily transported to anywhere in the world

NuMat Technologies solves the world's toughest problems at the atomic level. We do this by designing material-enabled hardware systems that uniquely store, harvest and produce high-value resources the world needs

Where others see billions of microbes intertwined within the crop microbiome, we see limitless possibilities to unlock powerful new solutions. At Pivot Bio, we’re pioneering a groundbreaking approach to crop nutrition — forging a path to better yields, healthier soils and a brighter future for our world

Plethora is a mission-driven startup that builds software, hardware, and operates a factory to empower everyone on Earth to invent anything

We specialize in the rapid development of biosensors for the detection of small molecules

Synthego is a leading provider of genome engineering solutions. Our flagship product, CRISPRevolution, is a portfolio of synthetic guide RNA designed for CRISPR genome editing and research. Synthego’s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.

Translating scientific breakthroughs into breakthrough products

Synthetic Genomics Inc. (SGI) is a global leader in the fields of synthetic biology and synthetic genomics utilizing our foundational intellectual property in these rapidly evolving disciplines to design and build biological systems to solve global sustainability challenges.

SGI provides solutions in genomics research, bioproduction, and applied products. Our research segment is focused on genomics solutions for academic and commercial R&D organizations. The commercial products and services include instrumentation, reagents, DNA synthesis services, and bioinformatics services and software.

About Tempo Automation

Tempo Automation is the world’s fastest electronics manufacturer for prototyping and low-volume production of printed circuit board assemblies. Developing and deploying proprietary factory automation software in its San Francisco smart factory, Tempo is changing the way companies in aerospace, medical technology, industrial technology, automotive, and consumer electronics innovate and bring new products to market. Tempo’s industry-leading speed, precision, and start-to-finish transparency enables agile hardware development. Customers are able to plan and execute product development and launch with levels confidence and certainty not previously possible.

Tempo’s investors include Point72 Ventures, Dolby Family Ventures, Lockheed Martin, Lux Capital, Uncork Capital, Bolt, Industry Ventures, Golden Seeds, Draper Associates, Cendana, OS Fund, AME, Incite Ventures, and Lockheed Martin Ventures. The company was founded in 2013.

Truvian is a healthcare company at the intersection of diagnostics and consumer tech. Our automated benchtop system is being developed to produce lab-accurate results for a full suite of health tests using a single, small sample of blood. Powered by patented technologies and intelligent integration, Truvian delivers a convenient and affordable alternative to off-site labs, providing immediate insights to inform healthcare decisions.

twoXAR is an artificial intelligence-driven drug discovery company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry and investor partnerships.

We use machine learning and human genomic data to accelerate the discovery of new treatments for patients with neurodegenerative diseases.

Vicarious is developing artificial general intelligence for robots. By combining insights from generative probabilistic models and systems neuroscience, our architecture trains faster, adapts more readily, and generalizes more broadly than AI approaches commonly used today.

Investment Exited - Exit News

Viv is an artificial intelligence platform that enables developers to distribute their products through an intelligent, conversational interface. It’s the simplest way for the world to interact with devices, services and things everywhere. Viv is taught by the world, knows more than it is taught, and learns every day.